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ABSTRACT
Background: Occult hepatitis B infection (OBI) is a form of hepatitis in which there is an absence of 
detectable HBsAg, despite the presence of HBV-DNA in the peripheral blood of patients. It seems that 
non-effective or attenuated immune system responses against HBV lead to the development of OBI. 
Previous studies showed that the Fas/Fas ligand (FasL) system is an important death signaling path-
way that is used by cytotoxic T lymphocytes to eradicate HBV from the liver.
Objectives: To investigate polymorphisms in the -670 region of the Fas gene in those with OBI.
Patients and Methods: The plasma samples from 3700 blood donors were tested for HBsAg and anti-
HBs by ELISA. The HBsAg-/anti-HBc+ samples were selected and screened for HBV-DNA by PCR. Those 
with HBV-DNA were diagnosed as OBI and PCR-RFLP technique was performed to examine polymor-
phisms within their Fas gene.
Results: 352 (9.5%) of 3700 blood samples were HBsAg-/anti-HBc+. HBV-DNA was detected in 57 (16.1%) 
of 352 HBsAg-/anti-HBc+ samples. Therefore, 57 HBsAg-/anti-HBc+/HBV-DNA+ patients were diagnosed 
as OBI. Patient and control groups had no significant differences in terms of the studied polymor-
phisms.
Conclusions: The functional polymorphisms in the promoter region of Fas gene are not associated 
with OBI. Therefore, it may be concluded that polymorphisms at the -670 position of the Fas gene do 
not have any critical effects on the immune response against HBV in OBI.
Background
Occult hepatitis B infection (OBI) is a clinical form of hepati-
tis B in which there are no detectable HBsAg in patient’s serum, 
despite being positive for HBV-DNA (1). Some of the patients do 
not have detectable HBV-DNA in serum, despite the presence of 
HBV-DNA in hepatocytes (2). Furthermore, high prevalence rates 
of OBI in chronic HCV-infected patients (3), hemodialysis pa-
tients (1, 4), immunocompromised patients (5) and HIV-infected 
patients (6) have been reported. OBI is clinically important be-
cause it may induce chronic liver disease (2) and cryptogenic 
cirrhosis (7). This type of hepatitis also poses a threat to blood 
transfusion services and its detection remains a significant chal-
lenge for these agencies. The high prevalence of OBI in Iranian 
blood donors (8-10) may be a critical risk for post-transfusion 
hepatitis (PTH), and despite appropriate screening of all donat-
ed blood and blood components for HBsAg, some cases of PTH B 
are reported (8, 11). The majority of PTH B infections are caused 
by OBI (12) which we previously reported in our investigations 
in Isfahan (9) and Kerman (10), the two central provinces of Iran. 
The mechanisms responsible for progression of OBI are yet to 
be clarified however, some investigators have suggested that 
genetic and immunological parameters may play a significant 
role in the resistance of some individuals and sensitivity of oth-
er patients (11, 13, 14). Previous studies showed that the Fas/Fas 
ligand (FasL) system is an important death signaling pathway 
that is used by cytotoxic T lymphocytes to eradicate HBV from 
the liver (15). Elevated expression of FasL was also reported dur-
ing HBV infection by some investigators (16, 17). Furthermore, 
several studies showed that the polymorphisms within the Fas 
(-670 A→G) gene can alter its expression (18, 19).
Objectives
This study was conducted to investigate the relation between 
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OBI and the functional polymorphisms within the promoter re-
gion of Fas gene.
Patients and Methods
Patients
Peripheral  blood  samples  were  collected  from  3700  volun-
teer blood donors of the Rafsanjan Blood Transfusion Services 
(Kerman, Iran) and placed in EDTA pre-coated 5.5-mL tubes. The 
samples were centrifuged at 3700 g for 4 min and the sera were 
collected. All sera were separated within 24 hrs of collection. If 
needed, serum samples were stored at  20 ºC for a maximum 
of two months or at  70 ºC, when longer storage was required 
for further processing. For analysis of polymorphisms a 2-mL 
aliquot  was  collected  from  patients  with  OBI  (57  cases)  and 
100 healthy controls (HBsAg-/anti-HBc+/HBV-DNA+). The study 
protocol was approved by the Ethical Committee of Rafsanjan 
University of Medical Sciences. All of the participants complet-
ed and signed an informed consent form which was designed 
based on the objectives of the study.
Detection of serological HBV markers
HBsAg  screening  tests  were  performed  by  enzyme-linked 
immuno-sorbent  assay  (ELISA)  (Behring,  Germany).  Anti-HBc 
screening  tests  were  performed  by  a  manual  microplate  en-
zyme immunoassay using an anti-HBc commercial kit (RADIM, 
Italy). The present method is based on a competitive enzyme im-
munoassay (EIA). All of the samples were also screened by ELISA 
(RADIM, Italy) for possible HCV, HIV and HTLV-1 infections.
HBV-DNA extraction from plasma samples
Viral DNA was purified from 200-μL of plasma samples. Briefly, 
each plasma sample was incubated at 72 ºC for 10 min and then 
cooled down to 4 ºC for 5 min in 200 μL proteinase K (200 μg/
mL) (Cinnagen, Iran). Following phenol/chloroform extraction 
(1:1), the viral DNA was precipitated with ethanol and the pellet 
was re-dissolved in DNase-free, deionized water (Cinnagen, Iran) 
and stored at  20 ºC for further use.
HBV-DNA polymerase chain reaction (PCR) and gel 
eletrophoresis
PCR was carried out in a 25-μL mixture containing 10 mM tris-
HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 5 units 
recombinant  TaqDNA  polymerase,  200  μM  of  each  dNTP,  0.6 
μM of each primer, and 5 μL of the DNA extracted from 200 μL 
of plasma. The sequences of all primers used in this study are 
shown in Table 1. For HBV analysis, the primers are designed to 
amplify a 500-bp amplicon of the surface antigen or S gene of 
the HBV genome. Fast temperature cycling was performed us-
ing a thermal cycler (C1000, Bio-Rad, USA). PCR amplification 
was performed using the touchdown method which included 
one cycle of 93 ºC for 60 sec, 60 ºC for 20 sec and 72 ºC for 40 sec, 
then five cycles of 93 ºC for 20 sec, 60 ºC to 56 ºC for 20 sec and 72 
ºC for 40 sec followed by 30 cycles of 93 ºC for 20 sec, 55 ºC for 20 
sec and 72 ºC for 40 sec. HBV genomic DNA provided by the Cin-
nagen company (Iran) and a negative patient sample were used 
as positive and negative controls, respectively. For the analysis 
of the PCR amplification, 10 μL of the amplified DNA were run 
on 2% agarose gel after addition of 4 μL of loading buffer using a 
chemi-doc-XRS system (Bio-Rad, USA). The presence of a 500-bp 
fragment indicated a positive result. In parallel with samples, a 
100-bp DNA ladder was also run on the gels to estimate the mo-
lecular weight of DNA fragments in the gel.
Genomic DNA extraction
Peripheral blood was collected in EDTA tubes and genomic 
DNA was extracted using a commercial kit (Bioneer, Korea) fol-
lowing the recommended procedures. Extracted DNA was ali-
quoted (for each patient sample) and stored at  20 ºC for further 
use.
Detection of polymorphisms
The gene polymorphisms were analyzed by the PCR-restricted 
fragment length polymorphism (PCR-RFLP) method. PCR of the 
Fas gene was performed in a volume of 50 μL containing 250 ng 
of DNA template, 200 μM of each dNTP (Cinnagen, Iran), 0.5 U 
Taq DNA polymerase (Cinnagen, Iran), 1x PCR buffer (Cinnagen, 
Iran), 3 mM MgCl2, and 5 pM of each specific primer (Table 1). 
The PCR conditions were; an initial denaturation at 95 ºC for 5 
min, followed by 35 cycles of melting at 95 ºC for 50 sec, suitable 
annealing temperature for 50 sec (Table 1), and extension at 72 
ºC for 50 sec, with a final extension step of 5 min at 72 ºC using 
a thermal cycler (C1000, Bio-Rad, USA). The expected size of the 
amplified PCR product used to detect the -670 amplicon of Fas 
was 233 bp. The ScrFI restriction enzyme (Fermantase, Finland) 
was used to distinguish the -670 A→G polymorphisms, which 
resulted in 189 plus 44-bp fragments in the case of the -670 G al-
lele. More than 10% of the samples were randomly selected and 
retested by appropriate PCR-RFLP techniques for confirmation; 
the results were 100% concordant. The digested products were 
run on a 2.5% agarose gel (Cinnagen, Iran) and analyzed using a 
chemi-doc-XRS system (Bio-Rad, USA) after staining with ethidi-
um bromide.
Statistical analysis
Hardy-Weinberg  equilibrium  was  assessed  using  genotype 
data.  Allele  and  genotype  frequencies  were  calculated  in  pa-
tients and healthy controls by direct gene counting. Statistical 
analysis of the differences between groups was determined by 
x2 test using EPI 2000 and SPSS® ver 13. A p<0.05 was considered 
statistically significant.   
Results
This study was performed on 3700 blood samples collected 
from patients attending the Rafsanjan blood transfusion servic-
es. All of the samples were found to be negative for HBsAg, anti-
HCV, anti-HTLV-1 and anti-HIV antibodies. Out of 3700 samples, 
  
Table 1. The sequence of the primers used in the study as well as the appropriate annealing temperatures and expected PCR product sizes
Target Genes                Primers                                           Annealing temperature           Product size (bp)
                               
S gene (HBV)
Fas (670)
F:5’ TCGTGGTGGACTTCTCTC 3’                         60 ºC                             500
R:5’ ACAGTGGGGGAAAGCCC 3’
Fas 670 F: 5' CTACCTAAGAGCTATCT ACCGTTC 3'                   58 ºC                                                                           233 
Fas 670 R: 5' GGCTGTCCATGTTGTGGCTGC 3'  Polymorphisms within Fas gene in occult HBV infection Arababadi MK et al. 25
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Discussion
It is now well established that following viral hepatitis, some 
of the infected hepatocytes express the Fas and FasL system (15, 
20). It is also stated that the rate of expression of FasL is corre-
lated with the kind of clinical presentation and also correlates 
with the different stages of the HBV infection and associated liv-
er disease (21). Furthermore, Fas/FasL system may play a key role 
in apoptosis of the infected hepatocytes (22). For example, over-
expression of Fas/FasL system in hepatocellular carcinoma (23), 
352 (9.5%) were positive for anti-HBc out of whom 57 were found 
positive for HBV-DNA (Figure 1); These 57 HBsAg-/anti-HBc+/HBV-
DNA+ patients were diagnosed as OBI. Results of this study indi-
cated that 16.1% of HBsAg-negative but anti-HBc-positive samples 
had detectable HBV-DNA which is 1.54% (57 of 3700) of the total 
collected samples. The mean±SD age of patients and controls 
were 28±6 and 28±8 years, respectively; there was no statisti-
cally significant difference in age between the two groups (Table 
2). Three (3%) of the control group members were female and 
97 (97%) were male while two of the patients (4%) were female 
and 55 (96%) were male. In addition, analysis of socio-economic 
conditions showed that there was also no significant difference 
between the patient and control groups (Table 2). Evaluation of 
the polymorphisms at  670 position of Fas showed that the fre-
quency of ‘A’ and ‘G’ alleles were 69 (60.5%) and 45 (39.5%) in pa-
tients, respectively; the values were 124 (62%) and 76 (38%) in con-
trols, respectively. Statistical analysis of these alleles indicated 
that the differences were not statistically significant (p=0.810) 
(Table  3).  Our  results  also  showed  that  the  prevalence  of  A/A 
genotype within the  670 region of Fas was 18 (32%) in patients 
and 40 (40%) in controls; the frequency of A/G genotype was 33 
(58%) and 44 (44%) in patients and controls, respectively; and the 
frequency of G/G genotype in patients was 6 (11%) and in controls 
was 16 (16%) (Table 3). Statistical analysis of our data could not 
show any significant difference between the two groups regard-
ing the frequencies of these genotypes (p=0.232).
 
              Variant                       Healthy control                            Patient 
                                                       (n=100)          (n=57)
28±8                           28±6 Age
(Mean±SD)(year)
3 (3%)                            2 (3.5%)
97 (97.8%)                                               55 (96.5%)
 
22 (22%)                            12 (21%)
47 (47%)                                                28 (49%)
31 (31%)                                                17 (30%)
Sex
     Female
     Male
Socio-economic     
status
     Weak
     Medium
     High 
Table 2. Demographic and socioeconomic conditions of OBI patients and controls
        
38 (67%)                    40 (40%)                  0.232
33 (58%)                    44 (44%)             
6 (11%)                    16 (16%) 
69 (60.5%)                   124 (62%)                   0.810
45 (39.5%)                    76 (38%)   
Variant                    Patients                    Control            p-value
                 No.(%)              No.(%)
Genotype
     A/A 
     A/G 
     G/G
Alleles
     A 
     G 
Table 3. The frequency of the  670 A→G polymorphisms within the Fas gene 
promoter of OBI patients and controls
Figure 1. HBV-DNA PCR. An ethidum bromide stained agarose gel showing typical 
results of HBV-DNA PCR screening of collected samples which were HBsAg nega-
tive and anti-HBc positive. Lane 1: DNA ladder marker; lane 2: A positive control 
showing the expected 500-bp product; lane 3: A negative control; lanes 4 and 5: 
Positive samples.
chronic HBV and HCV infection (15) and the fulminant form of 
HBV infection (24) were reported. It seems that over-expression 
of Fas/FasL led to hepatocyte injury in hepatitis (23, 24). Howev-
er, despite evidence suggesting a potential correlation between 
Fas/FasL system and disease status, our results showed that the 
frequency of evaluated alleles and genotypes was not different 
between OBI patients and healthy controls. Therefore, it can be 
concluded that these polymorphisms are not associated with 
OBI. Previous studies showed that the level of expression of Fas 
and FasL was associated with the clinical pattern of the disease 
(15, 25). For example, Bortolami et al. reported more expression 
of Fas and FasL in HBV-infected hepatocytes from patients with 
cirrhosis than in patients with chronic hepatitis (15). Studies 
also reported that polymorphisms in the promoter regions of 
Fas and FasL influence the pattern of their expression (26). Since 
OBI patients are unable to clear HBV completely, it could be sug-
gested that the expression of Fas and FasL in OBI patients may 
be compromised by mechanisms other than polymorphisms 
within the promoter region. Despite evidence linking a func-
tional role for Fas to progression of viral hepatic disease, our 
data showed that the polymorphisms, which are known to in-
fluence Fas expression levels, were not statistically different be-
tween OBI patients and healthy controls. Further studies should 
be done on the expression of Fas at the protein level to confirm 
this. To our knowledge, this is the first report which investigates 
the involvement of Fas polymorphisms with OBI. However, in 
related research, Jung et al. also showed that there were no sig-
nificant associations between FasL (844 C/T) polymorphism and 
HBV clearance in chronic hepatitis patients (22). Interestingly, 
similarly to our own findings, Sung and colleagues could not 
find a significant difference between the healthy donors and pa-
tients with hepatocellular carcinoma (21). Similarly, several stud-
ies reported a correlation between Fas and FasL polymorphisms 
during HCV infection (27-29). One reason for the discrepancy 
between our results and these studies could be explained by the 
different types of hepatitis infection (HCV) and there may also 
be genetic differences in the populations studied. In addition, 
there may also be subtle differences in the type of disease from 
our studied population. It is not clear through what mecha-
nisms OBI patients are unable to completely overcome the viral 
contamination, however, based on the current studies it seems 
that the polymorphisms within the promoter region of the Fas 
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